卡介苗与百白破疫苗接种对婴儿死亡率的非特异性影响:加纳与坦桑尼亚出生队列分析
研究基于加纳22955名和坦桑尼亚31999名新生儿的平行随机双盲安慰剂对照试验队列,随访至1岁,采用Cox比例风险模型分析卡介苗与百白破疫苗接种与婴儿生存的关联。结果显示两国卡介苗和百白破疫苗接种均与婴儿死亡风险降低相关,未发现与婴儿性别或新生儿维生素A补充的交互作用。
要点
- 卡介苗接种与加纳婴儿死亡风险降低相关(aHR 0.51,95%CI 0.38-0.68)。
- 卡介苗接种与坦桑尼亚婴儿死亡风险降低相关(aHR 0.08,95%CI 0.07-0.10)。
- 百白破疫苗接种与两国婴儿死亡风险降低相关,未发现与新生儿维生素A补充或性别的交互作用。
核心结论
- 卡介苗和百白破疫苗接种与加纳和坦桑尼亚婴儿死亡风险降低相关,未发现百白破或卡介苗疫苗、新生儿维生素A补充与婴儿性别之间的交互作用证据。
- 研究支持关于卡介苗和百白破疫苗接种的全球推荐以及确保所有儿童及时接种疫苗的项目努力。
研究设计与样本
- 研究纳入加纳22955名新生儿和坦桑尼亚31999名新生儿,来源于2010年至2014年开展的两项平行、随机、双盲、安慰剂对照的新生儿维生素A补充试验,随访至1岁。
- 采用Cox比例风险模型估计卡介苗和百白破疫苗接种与婴儿生存的关联。
主要发现
- 控制混杂因素后,卡介苗接种与加纳婴儿死亡风险降低相关(aHR 0.51,95%CI 0.38-0.68)。
- 控制混杂因素后,卡介苗接种与坦桑尼亚婴儿死亡风险降低相关(aHR 0.08,95%CI 0.07-0.10)。
- 接种百白破疫苗与加纳婴儿死亡风险降低相关(aHR 0.39,95%CI 0.26-0.59)。
- 接种百白破疫苗与坦桑尼亚婴儿死亡风险降低相关(aHR 0.19,95%CI 0.16-0.22)。
- 未发现卡介苗或百白破疫苗接种状态与婴儿性别或新生儿维生素A补充之间存在交互作用的证据。
临床怎么用
- 研究支持关于卡介苗和百白破疫苗接种的全球推荐以及确保所有儿童及时接种疫苗的项目努力。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Vaccines may induce non-specific effects on survival and health outcomes, in addition to protection against targeted pathogens or disease. Observational evidence suggests that infant Baccillus Calmette-Guérin (BCG) vaccination may provide non-specific survival benefits, while diphtheria-tetanus-pertussis (DTP) vaccination may increase the risk of mortality. Non-specific vaccine effects have been hypothesized to modify the effect of neonatal vitamin A supplementation (NVAS) on mortality. METHODS: 22,955 newborns in Ghana and 31,999 newborns in Tanzania were enrolled in two parallel, randomized, double-blind, placebo-controlled trials of neonatal vitamin A supplementation from 2010 to 2014 and followed until 1-year of age. Cox proportional hazard models were used to estimate associations of BCG and DTP vaccination with infant survival. RESULTS: BCG vaccination was associated with a decreased risk of infant mortality after controlling for confounders in both countries (Ghana adjusted hazard ratio (aHR): 0.51, 95% CI: 0.38-0.68; Tanzania aHR: 0.08, 95% CI: 0.07-0.10). Receiving a DTP vaccination was associated with a decreased risk of death (Ghana aHR: 0.39, 95% CI: 0.26-0.59; Tanzania aHR: 0.19, 95% CI: 0.16-0.22). There was no evidence of interaction between BCG or DTP vaccination status and infant sex or NVAS. CONCLUSION: We demonstrated that BCG and DTP vaccination were associated with decreased risk of infant mortality in Ghana and Tanzania with no evidence of interaction between DTP or BCG vaccination, NVAS, and infant sex. Our study supports global recommendations on BCG and DTP vaccination and programmatic efforts to ensure all children have access to timely vaccination. CLINICAL TRIALS REGISTRATION: Ghana (Australian New Zealand Clinical Trials Registry (ANZCTR): ACTRN12610000582055) and Tanzania (ANZCTR: ACTRN12610000636055).
引用
- Quinn MK, Edmond KM, Fawzi WW, et al. Non-specific effects of BCG and DTP vaccination on infant mortality: An analysis of birth cohorts in Ghana and Tanzania. Vaccine. 2022. PMID: 35618557. doi:10.1016/j.vaccine.2022.04.082
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。